Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis.

Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D.

Lupus Sci Med. 2017 Aug 31;4(1):e000229. doi: 10.1136/lupus-2017-000229. eCollection 2017.

2.

ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.

Khoury SJ, Rochon J, Ding L, Byron M, Ryker K, Tosta P, Gao W, Freedman MS, Arnold DL, Sayre PH, Smilek DE; ACCLAIM Study Group.

Mult Scler. 2017 Apr;23(5):686-695. doi: 10.1177/1352458516662727. Epub 2016 Aug 5.

3.

Solving the puzzle of autoimmunity: critical questions.

Smilek DE, St Clair EW.

F1000Prime Rep. 2015 Feb 3;7:17. doi: 10.12703/P7-17. eCollection 2015. Review.

4.

Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort.

Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M.

Arthritis Rheumatol. 2015 May;67(5):1305-13. doi: 10.1002/art.39026.

5.

Restoring the balance: immunotherapeutic combinations for autoimmune disease.

Smilek DE, Ehlers MR, Nepom GT.

Dis Model Mech. 2014 May;7(5):503-13. doi: 10.1242/dmm.015099. Review.

6.
7.
8.

Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide.

Devaux B, Enderlin F, Wallner B, Smilek DE.

J Neuroimmunol. 1997 May;75(1-2):169-73.

PMID:
9143251
10.

Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules.

Schlegel PG, Aharoni R, Smilek DE, Fernandez LP, McDevitt HO, Tran N, Vaysburd M, Chao NJ.

Blood. 1994 Oct 15;84(8):2802-10.

11.

Minimum structural requirements for peptide presentation by major histocompatibility complex class II molecules: implications in induction of autoimmunity.

Gautam AM, Lock CB, Smilek DE, Pearson CI, Steinman L, McDevitt HO.

Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):767-71.

12.

A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis.

Gautam AM, Pearson CI, Smilek DE, Steinman L, McDevitt HO.

J Exp Med. 1992 Aug 1;176(2):605-9.

13.

Inhibition of experimental autoimmune encephalomyelitis by a nonimmunogenic non-self peptide that binds to I-Au.

Gautam AM, Pearson CI, Sinha AA, Smilek DE, Steinman L, McDevitt HO.

J Immunol. 1992 May 15;148(10):3049-54.

PMID:
1578131
14.

MHC-binding peptides for immunotherapy of experimental autoimmune disease.

Wraith DC, Smilek DE, Webb S.

J Autoimmun. 1992 Apr;5 Suppl A:103-13. Review.

PMID:
1380239
15.

A role for major histocompatibility complex-binding peptides in the immunotherapy of autoimmune disease.

Wraith DC, Smilek DE.

Springer Semin Immunopathol. 1992;14(1):95-101. Review. No abstract available.

PMID:
1440200
16.

EAE: a model for immune intervention with synthetic peptides.

Smilek DE, Gautam AM, Pearson C, Steinman L, McDevitt HO.

Int Rev Immunol. 1992;9(3):223-30. Review.

PMID:
1285062
17.

A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis.

Smilek DE, Wraith DC, Hodgkinson S, Dwivedy S, Steinman L, McDevitt HO.

Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9633-7.

18.

Antigen recognition and peptide-mediated immunotherapy in autoimmune disease.

Smilek DE, Lock CB, McDevitt HO.

Immunol Rev. 1990 Dec;118:37-71. Review. No abstract available.

PMID:
1706681
19.

T cell recognition in experimental autoimmune encephalomyelitis: prospects for immune intervention with synthetic peptides.

Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO.

Int Rev Immunol. 1990;6(1):37-47. Review.

PMID:
1715375
20.

Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy.

Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO.

Cell. 1989 Oct 20;59(2):247-55.

PMID:
2478291
21.

Evolution, function, and utilization of major histocompatibility complex polymorphism in autoimmune disease.

McDevitt HO, Wraith DC, Smilek DE, Lundberg AS, Steinman L.

Cold Spring Harb Symp Quant Biol. 1989;54 Pt 2:853-7. Review. No abstract available.

PMID:
2701219
22.

Class I major histocompatibility gene products of the brown Norway rat display two major antigenic regions.

Klinman DM, Smilek DE, McKearn TJ.

J Immunol. 1982 Sep;129(3):1204-8.

PMID:
6179998
23.

Monoclonal rat anti-MHC alloantibodies detect HLA-linked polymorphisms in humans.

Boyd HC, Smilek DE, Spielman RS, Zmijewski CM, McKearn TJ.

Immunogenetics. 1981;12(3-4):313-9.

PMID:
6970722
24.

Monoclonal rat anti-major histocompatibility complex antibodies display specificity for rat, mouse, and human target cells.

Smilek DE, Boyd HC, Wilson DB, Zmijewski CM, Fitch FW, McKearn TJ.

J Exp Med. 1980 May 1;151(5):1139-50.

25.

Properties of rat anti-MHC antibodies produced by cloned rat-mouse hybridomas.

McKearn TJ, Fitch FW, Smilek DE, Sarmiento M, Stuart FP.

Immunol Rev. 1979;47:91-115. Review. No abstract available.

PMID:
398328

Supplemental Content

Loading ...
Support Center